AGXT Antibody (2D10) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-31960

Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2b Kappa Clone # 2D10
Format
BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Recombinant AGXT (330-392aa) purified from E. coli
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2b Kappa
Applications for AGXT Antibody (2D10) - BSA Free
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS (pH 7.4), 10% Glycerol
Format
BSA Free
Preservative
0.02% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: AGXT
Alternate Names
AGT1L-alanine: glyoxylate aminotransferase 1, AGThepatic peroxisomal alanine:glyoxylate aminotransferase, AGXT1, alanine-glyoxylate aminotransferase, Alanine--glyoxylate aminotransferase, EC 2.6.1.44, EC 2.6.1.51, PH1, serine:pyruvate aminotransferase, SPATserine-pyruvate aminotransferase, SPTserine--pyruvate aminotransferase, TLH6
Gene Symbol
AGXT
Additional AGXT Products
Product Documents for AGXT Antibody (2D10) - BSA Free
Product Specific Notices for AGXT Antibody (2D10) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...